Influenza therapy.
D000081:Acetamides / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D003362:Cost-Benefit Analysis; D003401:Creatine / Q000652:urine; D004196:Disease Outbreaks / Q000191:economics / Q000517:prevention & control; D024882:Drug Resistance, Viral; D006146:Guanidines; D006801:Humans; D009980:Influenza A virus; D007251:Influenza, Human / Q000150:complications / Q000191:economics / Q000628:therapy* / Q000821:virology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism; D008657:Metabolic Clearance Rate; D053139:Oseltamivir; D018579:Patient Selection; D011322:Primary Prevention / Q000191:economics / Q000379:methods; D011714:Pyrans; D012794:Sialic Acids / Q000627:therapeutic use; D016896:Treatment Outcome; D053243:Zanamivir
D000081:Acetamides; D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053139:Oseltamivir; D000547:Amantadine; D053243:Zanamivir; D003401:Creatine